SCHEMBL10193223

SCHEMBL10193223

CS/C(N)=N\Cc1cccc(NS(C)(=O)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 3/20 0.43
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 1/20 0.41
PMP22 Q01453 1/20 0.41
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
CYP3A4 P08684 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10193018 0.80 AOC3 (0.52) SMN1; SMN2ALDH1A1POLBCYP1A2HSD17B10
SCHEMBL13513281 0.75 ALDH1A1 (0.54) NR3C1SMN1; SMN2ALDH1A1DRD2DRD4
SCHEMBL9062832 0.74 NOS1 (0.68) SMN1; SMN2ALDH1A1DRD3GRIN2DGRIN3B
SCHEMBL843461 0.74 NR3C1 (0.47) NR3C1SMN1; SMN2ALDH1A1DRD2DRD4
SCHEMBL876253 0.74 NR3C1 (0.47) NR3C1SMN1; SMN2ALDH1A1DRD2DRD4
SCHEMBL3560306 0.74 IKBKB (0.58) NR3C1SMN1; SMN2ALDH1A1DRD2DRD4
SCHEMBL2284909 0.74 HTR6 (0.64) NR3C1SMN1; SMN2ALDH1A1DRD2DRD4
Hydrochloric Acid SCHEMBL27533178 0.73 ALDH1A1 (0.53) NR3C1SMN1; SMN2ALDH1A1DRD2DRD4
Hydrochloric Acid SCHEMBL2554758 0.72 HTR6 (0.62) NR3C1SMN1; SMN2ALDH1A1DRD2DRD4
SCHEMBL10192939 0.72 CYP1A2 (0.57) ALDH1A1LMNACYP3A4CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2415756-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY Shionogi&Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120015961-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015961-A1 ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, BACE2, APP NR3C1 348/4885SMN1; SMN2 1139/4885ALDH1A1 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.